Tyrosine kinase inhibitor compound and preparation method thereof

Various crystal forms of the compound of Formula 1 are prepared by dissolving and slowly evaporating or stirring crystallization in different solvents, which solves the problems of poor light stability and harsh preparation conditions, and achieves the improvement of high stability and bioavailability. Suitable for industrial production.

CN119019365AActive Publication Date: 2024-11-26CHENGDU EASTON BIOPHARMACEUTICALS CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411005766.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-01-31
Filing Date
2024-07-25
Publication Date
2024-11-26
Estimated Expiration
2044-07-25

AI Technical Summary

Technical Problem

The light stability of the compounds of Formula 1 and the preparation conditions are harsh, resulting in increased impurities and transcrystallization phenomena during storage and use, affecting the stability and bioavailability of the drug.

Method used

通过在不同溶剂中溶解并缓慢挥发或搅拌析晶的方法制备多种晶型I、II、III、IV、V、VI、VII,优化其X-射线粉末衍射图谱特征峰,提高其结晶度、 Solubility and chemical stability.

Benefits of technology

The crystal form II of the compound of formula 1 prepared has high crystallinity, physical and chemical stability, improves light stability, improves bioavailability, and reduces moisture-induced and dissolving, making it suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention relates to the field of medicine crystal forms, in particular to a novel crystal form of a compound shown in the formula 1 and a preparation method of the novel crystal form, and the novel crystal form of the compound shown in the formula 1 has excellent physical stability and chemical stability, high solubility and bioavailability, good fluidity and low hygroscopicity. In addition, the novel crystal form of the compound as shown in the formula 1 is mild in preparation condition, simple to operate, good in process reproducibility, high in purity and suitable for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of drug crystal forms, and specifically relates to a new crystal form of a compound of formula 1 and a preparation method thereof. Background Art

[0002] The compound of formula 1 is a Class 1.1 anti-tumor new drug independently developed by Zhengda Tianqing Pharmaceutical Group. The compound of formula 1 was approved for marketing in May 2018 for the treatment of patients with advanced non-small cell carcinoma. Subsequently, the drug was approved for the treatment of patients with soft tissue sarcoma, small cell lung cancer, and medullary thyroid disease. The chemical structure of the compound of formula 1 is shown below:

[0003]

[0004] Patent CN102344438A discloses three crystalline forms of the compound of Formula 1, namely anhydrous form A, anhydrous form B and dihydrate form C. According to the patent, the impurity content of the three forms increased significantly after being placed under light for 10 days, indicating that the photostability of the compound of Formula 1 is poor. In addition, the preparation conditions of Form A and Form B are relatively harsh, and both need to be obtained by vacuum drying at 80-85°C. Higher drying temperatures may further lead to the generation of degradation impurities, increasing the difficulty of process control.

[0005] As is known to all, different crystal forms of the same drug may differ significantly in appearance, solubility, melting point, dissolution, etc., thus affecting the stability, bioavailability and efficacy of the drug. Generally speaking, a stable crystal form has a higher melting point, lower solubility and slower dissolution rate; an unstable crystal form, on the contrary, is easily transformed into other crystal forms. Selecting the most thermodynamically stable crystal form can ensure that crystal transformation does not occur during the production and storage and transportation of the raw material drug, but the stable crystal form often has poor bioavailability due to its low solubility, so it is necessary to develop a pharmaceutical crystal form that can take into account both stability and solubility / bioavailability. Therefore, it is necessary to study the crystal form of the compound of formula 1 and develop one or more crystal forms with simple preparation methods, high chemical stability, good solubility, high purity, low hygroscopicity and suitable for industrial production. Summary of the invention

[0006] In view of the defects of the compounds of formula I in the prior art, such as poor photostability and harsh preparation conditions, the present application provides one or more pharmaceutically acceptable crystal forms having advantages in comprehensive performance in terms of stability, hygroscopicity, solubility, bioavailability, etc., as well as a method for preparing a crystal form of the compound of formula I with simple steps, low cost, and conducive to industrial production.

[0007] The present application provides a crystalline form I of a compound of formula 1, whose X-ray powder diffraction pattern has characteristic peaks at 2θ angles of 6.3±0.2°, 8.5±0.2°, 10.1±0.2°, 12.4±0.2°, 16.0±0.2°, 17.0±0.2°, 24.5±0.2° and 28.3±0.2°.

[0008] Furthermore, the X-ray powder diffraction pattern of the crystalline form I has characteristic peaks at 2θ angles of 6.3±0.2°, 7.8±0.2°, 8.5±0.2°, 9.4±0.2°, 10.1±0.2°, 12.4±0.2°, 15.7±0.2°, 16.0±0.2°, 17.0±0.2°, 19.5±0.2°, 24.5±0.2°, 28.3±0.2° and 29.4±0.2°.

[0009] Furthermore, the X-ray powder diffraction pattern of the crystalline form I is substantially as follows Figure 1 shown.

[0010] The present application also relates to a method for preparing the crystalline form I of the compound of formula 1, which specifically comprises: adding the compound of formula 1 to pure water or a mixed solvent of an organic solvent and water to dissolve it, and then slowly volatilizing it, and the resulting solid is the crystalline form I of the compound of formula 1.

[0011] Furthermore, the organic solvent is selected from isopropanol, ethyl acetate, isopropyl acetate, acetonitrile, tetrahydrofuran, 2-methyltetrahydrofuran, methyl isobutyl ketone, diethyl ether, methyl tert-butyl ether, petroleum ether, dichloromethane or toluene.

[0012] Furthermore, the volatilization temperature is 5 to 50°C.

[0013] Furthermore, the method for preparing the crystalline form I of the compound of formula 1 is specifically: adding the compound of formula 1 to a mixed solvent of an organic solvent and water (the volume fraction of water is 5%) to dissolve, placing the solution at 5 to 50° C. to slowly evaporate, and the obtained solid is the crystalline form I of the compound of formula 1.

[0014] Furthermore, another method for preparing the crystalline form I of the compound of formula 1 is as follows: adding the compound of formula 1 into pure water to dissolve it, placing the solution at 5 to 50° C. to slowly evaporate it, and the resulting solid is the crystalline form I of the compound of formula 1.

[0015] The present application provides a crystalline form II of a compound of formula 1, whose X-ray powder diffraction pattern has characteristic peaks at 2θ angles of 8.6±0.2°, 10.1±0.2°, 14.5±0.2°, 17.3±0.2°, 18.0±0.2°, 22.5±0.2°, 25.9±0.2° and 28.4±0.2°.

[0016] Furthermore, the X-ray powder diffraction pattern of the crystalline form II has characteristic peaks at 2θ angles of 8.6±0.2°, 10.1±0.2°, 14.5±0.2°, 17.3±0.2°, 18.0±0.2°, 22.2±0.2°, 22.5±0.2°, 22.7±0.2°, 25.9±0.2°, 27.8±0.2° and 28.4±0.2°.

[0017] Furthermore, the X-ray powder diffraction pattern of the crystalline form II has characteristic peaks at 2θ angles of 8.6±0.2°, 10.1±0.2°, 13.7±0.2°, 14.5±0.2°, 15.3±0.2°, 15.7±0.2°, 17.3±0.2°, 18.0±0.2°, 22.2±0.2°, 22.5±0.2°, 22.7±0.2°, 25.9±0.2°, 27.8±0.2° and 28.4±0.2°.

[0018] Furthermore, the X-ray powder diffraction pattern of the crystalline form II is substantially as follows Figure 2 shown.

[0019] The present application also relates to a method for preparing crystal form II, which specifically comprises: adding the compound of formula 1 into pure water to dissolve, then adding acetonitrile to stir and crystallize, filtering, and drying to obtain crystal form II of the compound of formula 1.

[0020] Furthermore, the volume ratio of the pure water to acetonitrile is 1:10 to 1:60.

[0021] Furthermore, the preparation method is specifically as follows: adding the compound of formula 1 into pure water to dissolve, adding acetonitrile at 0-40°C, then stirring and crystallizing at 0-40°C, filtering, and air drying or vacuum drying at 30-60°C for 6-48 hours to obtain the crystalline form II of the compound of formula 1.

[0022] The present application provides a crystalline form III of a compound of formula 1, whose X-ray powder diffraction pattern has characteristic peaks at 2θ angles of 5.9±0.2°, 8.8±0.2°, 13.8±0.2°, 15.9±0.2°, 18.1±0.2°, 21.4±0.2° and 22.1±0.2°.

[0023] Furthermore, the X-ray powder diffraction pattern of the crystalline form III has characteristic peaks at 2θ angles of 5.9±0.2°, 8.8±0.2°, 13.8±0.2°, 15.9±0.2°, 18.1±0.2°, 20.5±0.2°, 20.8±0.2°, 21.4±0.2°, 22.1±0.2°, 22.5±0.2°, 23.5±0.2°, 24.4±0.2° and 26.6±0.2°.

[0024] Furthermore, the X-ray powder diffraction pattern of the crystalline form III of the compound of formula 1 has characteristic peaks at 2θ angles of 5.9±0.2°, 7.9±0.2°, 8.8±0.2°, 13.8±0.2°, 14.8±0.2°, 15.9±0.2°, 18.1±0.2°, 20.5±0.2°, 20.8±0.2°, 21.4±0.2°, 22.1±0.2°, 22.5±0.2°, 23.5±0.2°, 24.4±0.2° and 26.6±0.2°.

[0025] Furthermore, the X-ray powder diffraction pattern of the crystalline form III of the compound of formula 1 is substantially as follows Figure 3 shown.

[0026] The present application also relates to a method for preparing the crystalline form III of the compound of formula 1, specifically: adding the compound of formula 1 to dimethyl sulfoxide to obtain a clear solution, then adding N,N-dimethylacetamide, stirring and crystallizing, filtering, and drying to obtain the crystalline form III of the compound of formula 1.

[0027] Furthermore, the preparation method is specifically as follows: adding the compound of formula 1 to dimethyl sulfoxide to obtain a clear solution, adding N,N-dimethylacetamide to stir and crystallize, filtering, and drying at 30 to 60° C. for 6 to 24 hours to obtain the crystalline form III of the compound of formula 1.

[0028] The present application provides a crystalline form IV of a compound of formula 1, whose X-ray powder diffraction pattern has characteristic peaks at 2θ angles of 5.0±0.2°, 7.4±0.2°, 8.4±0.2°, 9.9±0.2°, 14.2±0.2° and 19.8±0.2°.

[0029] Furthermore, the X-ray powder diffraction pattern of the crystalline form IV has characteristic peaks at 2θ angles of 5.0±0.2°, 7.4±0.2°, 8.4±0.2°, 9.9±0.2°, 14.2±0.2°, 14.9±0.2°, 19.8±0.2°, 22.0±0.2°, 24.2±0.2° and 25.3±0.2°.

[0030] Furthermore, the X-ray powder diffraction pattern of the crystalline form IV has characteristic peaks at 2θ angles of 5.0±0.2°, 7.4±0.2°, 8.4±0.2°, 8.7±0.2°, 9.9±0.2°, 13.3±0.2°, 14.2±0.2°, 14.9±0.2°, 18.3±0.2°, 19.8±0.2°, 22.0±0.2°, 24.2±0.2° and 25.3±0.2°.

[0031] Furthermore, the X-ray powder diffraction pattern of the crystalline form IV is substantially as follows Figure 4 shown.

[0032] The present application also relates to a method for preparing the crystal form IV, which specifically comprises: adding the compound of formula 1 into tetrahydrofuran, suspending at high temperature, filtering, and drying to obtain the crystal form IV of the compound of formula 1.

[0033] Furthermore, the high temperature is 50-60°C.

[0034] Furthermore, the preparation method is specifically as follows: adding the compound of formula 1 to tetrahydrofuran, suspending at 50-60° C. for 12-24 hours, filtering, and drying at 30-60° C. for 6-24 hours to obtain the crystalline form IV of the compound of formula 1.

[0035] The present application provides a crystalline form V of a compound of formula 1, whose X-ray powder diffraction pattern has characteristic peaks at 2θ angles of 5.9±0.2°, 9.7±0.2°, 11.8±0.2°, 15.5±0.2°, 17.8±0.2°, 20.5±0.2° and 25.9±0.2°.

[0036] Furthermore, the X-ray powder diffraction pattern of the type V has characteristic peaks at 2θ angles of 5.9±0.2°, 9.7±0.2°, 11.8±0.2°, 15.5±0.2°, 17.8±0.2°, 20.5±0.2°, 23.4±0.2°, 23.9±0.2° and 25.9±0.2°.

[0037] Furthermore, the X-ray powder diffraction pattern of the crystalline form V is substantially as follows Figure 5 shown.

[0038] The present application also relates to a method for preparing the crystal form V, which is specifically: adding the compound of formula 1 to hexafluoroisopropanol, suspending at high temperature, filtering, and drying to obtain the crystal form V of the compound of formula 1.

[0039] Furthermore, the high temperature is 50-60°C.

[0040] Furthermore, the preparation method is specifically as follows: adding the compound of formula 1 to hexafluoroisopropanol, suspending at 50-60° C. for 12-24 hours, filtering, and drying at 30-60° C. for 6-24 hours to obtain the crystalline form V of the compound of formula 1.

[0041] The present application provides a crystalline form VI of a compound of formula 1, whose X-ray powder diffraction pattern has characteristic peaks at 2θ angles of 6.8±0.2°, 10.5±0.2°, 14.9±0.2°, 19.3±0.2°, 22.0±0.2° and 25.6±0.2°.

[0042] Furthermore, the X-ray powder diffraction pattern of the crystalline form VI has characteristic peaks at 2θ angles of 6.8±0.2°, 10.5±0.2°, 14.9±0.2°, 17.1±0.2°, 19.3±0.2°, 22.0±0.2°, 25.6±0.2°, 27.1±0.2° and 28.3±0.2°.

[0043] Furthermore, the X-ray powder diffraction pattern of the crystalline form VI has characteristic peaks at 2θ angles of 6.8±0.2°, 9.3±0.2°, 10.5±0.2°, 14.9±0.2°, 15.9±0.2°, 17.1±0.2°, 19.3±0.2°, 22.0±0.2°, 25.6±0.2°, 27.1±0.2° and 28.3±0.2°.

[0044] Furthermore, the X-ray powder diffraction pattern of the crystalline form VI is substantially as follows Figure 6 shown.

[0045] The present application also relates to a method for preparing crystal form VI, which specifically comprises: adding the compound of formula 1 to a mixed solvent of trifluoroethanol / water, stirring to dissolve, and slowly volatilizing to obtain crystal form VI of the compound of formula 1.

[0046] Furthermore, the preparation method is specifically as follows: adding the compound of formula 1 to a mixed solvent of trifluoroethanol / water, stirring to dissolve, and slowly volatilizing at 5-35° C. to obtain the crystal form VI of the compound of formula 1.

[0047] The present application provides a crystalline form VII of a compound of formula 1, whose X-ray powder diffraction pattern has characteristic peaks at 2θ angles of 4.4±0.2°, 8.4±0.2°, 15.2±0.2°, 19.9±0.2°, 23.5±0.2° and 26.2±0.2°.

[0048] Furthermore, the X-ray powder diffraction pattern of the crystalline form VII has characteristic peaks at 2θ angles of 4.4±0.2°, 8.4±0.2°, 15.2±0.2°, 19.9±0.2°, 22.3±0.2°, 23.5±0.2°, 26.2±0.2°, 26.9±0.2°, 28.5±0.2° and 31.7±0.2°.

[0049] Furthermore, the X-ray powder diffraction pattern of the crystalline form VII has characteristic peaks at 2θ angles of 4.4±0.2°, 7.5±0.2°, 8.4±0.2°, 13.0±0.2°, 15.2±0.2°, 19.9±0.2°, 22.3±0.2°, 23.5±0.2°, 26.2±0.2°, 26.9±0.2°, 28.5±0.2° and 31.7±0.2°.

[0050] Furthermore, the X-ray powder diffraction pattern of the crystalline form VII is substantially as follows Figure 7 shown.

[0051] The present application also relates to a method for preparing the crystalline form VII, which specifically comprises: drying the crystalline form I of the compound of formula 1 at high temperature to obtain the crystalline form VII of the compound of formula 1.

[0052] Furthermore, the high temperature is 40-60°C.

[0053] Furthermore, the preparation method is specifically as follows: drying the crystal form I of the compound of formula 1 at 40-60° C. by forced air drying or vacuum drying for 6-48 hours to obtain the crystal form VII of the compound of formula 1.

[0054] The beneficial effects brought by this application are:

[0055] 1. The crystalline form II of the compound of formula 1 prepared in the present application has higher crystallinity, better physical stability and chemical stability, which is beneficial to the production and storage of raw materials and preparations.

[0056] 2. The crystalline form II of the compound of formula 1 prepared in the present application has improved photostability, which is beneficial to reduce the content of photochemical degradation products produced during the storage of raw materials and preparations, and is also beneficial to reduce the possibility of the compound causing photosensitivity reactions due to exposure to sunlight in patients receiving the corresponding drugs.

[0057] 3. The crystalline form II of the compound of formula 1 prepared in the present application has high solubility and bioavailability.

[0058] 4. The crystal form II of the compound of formula 1 prepared in the present application has lower hygroscopicity while maintaining a high solubility, thus overcoming the defect of the existing crystal form that it is easy to transform into a crystal due to its high hygroscopicity.

[0059] 5. The crystalline form II of the compound of formula 1 prepared in the present application has good dispersibility and fluidity, is not prone to adhesion and agglomeration when filling capsules, and the filled capsules have good content uniformity.

[0060] 6. The crystalline form II of the compound of formula 1 obtained in the present application has lower residual solvent and higher purity, and the preparation conditions are mild, the operation is simple, and the process reproducibility is good, so that the conditions for industrial production are controllable, which is conducive to large-scale industrialization. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] Figure 1 The XRD pattern of the crystalline form I of the compound of formula 1 is shown in FIG.

[0062] Figure 2 The XRD pattern of the compound of formula 1, crystal form II.

[0063] Figure 3 It is the XRD pattern of the crystalline form III of the compound of formula 1.

[0064] Figure 4 It is the XRD pattern of the crystalline form IV of the compound of formula 1.

[0065] Figure 5 The XRD pattern of the crystalline form V of the compound of formula 1 is shown in FIG.

[0066] Figure 6 The XRD pattern of the compound of formula 1, crystal form VI.

[0067] Figure 7 It is the XRD pattern of the crystalline form VII of the compound of formula 1.

[0068] Figure 8 The XRD pattern of Form A of the compound of Formula 1 is shown in FIG.

[0069] Fig. 9 The XRD pattern of the crystalline form C of the compound of formula 1 is shown in FIG.

[0070] Fig.10 The XRD comparison graphs of Form II of the compound of Formula 1 before and after the influencing factors are placed.

[0071] Fig.11 The XRD comparison chart of the crystalline form A of the compound of formula 1 before and after the influencing factors are placed.

[0072] Fig.12 The XRD comparison graphs of the crystalline form C of the compound of formula 1 before and after the influencing factors are placed.

[0073] Fig.13 DVS curve of the crystal form II of the compound of formula 1

[0074] Fig.14 DVS curve of the crystalline form A of the compound of formula 1

[0075] Fig.15 DVS curve of the crystalline form C of the compound of formula 1 DETAILED DESCRIPTION

[0076] The present application is further described in detail below in conjunction with the embodiments, but this is not intended to limit the present application. Any equivalent substitutions in the art made according to the disclosure of the present application shall fall within the protection scope of the present application.

[0077] The abbreviations used in this application are explained as follows:

[0078] XRD: X-ray powder diffraction

[0079] The X-ray powder diffraction (XRD) test described in this application is collected using a Malvern Panalytical Empyrea powder diffractometer, and the specific parameters are as follows:

[0080]

[0081] In the X-ray powder diffraction pattern of the present application, the error of the 2θ diffraction angle is ±0.20°.

[0082] The compound of formula 1 used in this application was purchased from Shanghai Yuanhua Pharmaceutical Technology Co., Ltd.

[0083] Example 1: Preparation of Form I of Compound of Formula 1

[0084] At 25°C, 300 mg of the compound of formula 1 was added to 31.5 mL of a mixed solvent of ethyl acetate and water (the volume fraction of water was 5%), and a clear solution was obtained after stirring. The solution was slowly evaporated at 50°C for 48 hours, and the obtained solid was the crystalline form I of the compound of formula 1. The obtained sample was subjected to X-ray powder determination using Cu-ka rays, and its spectrum had the diffraction angle, interplanar spacing and relative intensity shown in Table 1, and its X-ray powder diffraction spectrum was basically as shown in Table 1. Figure 1 shown.

[0085] Table 1 Diffraction angle, interplanar spacing and relative intensity of the crystalline form I of the compound of formula 1

[0086]

[0087] Example 2: Preparation of Form I of the Compound of Formula 1

[0088] At 25°C, 20 mg of the compound of formula 1 was added to a mixed solvent of 2 mL of methyl isobutyl ketone and 0.1 mL of water to obtain a clear solution, which was slowly evaporated at 5°C for 48 hours to obtain a solid, which was the crystalline form I of the compound of formula 1. The obtained sample was subjected to X-ray powder determination using Cu-ka rays, and its X-ray powder diffraction pattern was substantially consistent with that of Example 1.

[0089] Example 3: Preparation of Crystalline Form II of Compound of Formula 1

[0090] At 20°C, 1.0 g of the compound of formula 1 was added to 0.67 mL of pure water to dissolve, and then 20.1 mL of acetonitrile was added and stirred for 30 min. The mixture was then placed in a 0°C low temperature tank for stirring and crystallization, filtered, and dried in a vacuum drying oven at 30°C for 48 h to obtain the crystal form II of the compound of formula 1 with a purity of 99.26% and an acetonitrile residue of 0.006%. The obtained sample was subjected to X-ray powder determination using Cu-ka rays, and its spectrum had the diffraction angle, interplanar spacing and relative intensity shown in Table 2, and its X-ray powder diffraction spectrum was substantially as shown in Table 2. Figure 2 shown.

[0091] Table 2 Diffraction angle, interplanar spacing and relative intensity of the crystal form II of the compound of formula 1

[0092]

[0093]

[0094] Example 4: Preparation of Crystalline Form II of the Compound of Formula 1

[0095] At 20°C, 1.0 g of the compound of formula 1 was added to 0.67 mL of pure water for dissolution, followed by the addition of 40.2 mL of acetonitrile, followed by stirring for 30 min, and then placed in a 15°C low temperature tank for stirring and crystallization, filtered, and dried in a 60°C vacuum drying oven for 6 h to obtain the crystal form II of the compound of formula 1, with a purity of 99.18% and acetonitrile residue of 0.005%. The obtained sample was subjected to X-ray powder determination using Cu-ka rays, and its X-ray powder diffraction pattern was substantially consistent with that of Example 3.

[0096] Example 5: Preparation of Crystalline Form II of the Compound of Formula 1

[0097] At 40°C, 1.0 g of the compound of formula 1 was added to 0.67 mL of pure water to dissolve, followed by the addition of 26.8 mL of acetonitrile, stirred at the temperature for 36 h, filtered, and dried in a 60°C blast drying oven for 36 h to obtain the crystalline form II of the compound of formula 1, with a purity of 99.11% and 0 acetonitrile residue. The obtained sample was subjected to X-ray powder determination using Cu-ka rays, and its X-ray powder diffraction pattern was substantially consistent with that of Example 3.

[0098] Example 6: Preparation of Crystalline Form II of the Compound of Formula 1

[0099] At 25°C, 60 mg of the compound of formula 1 was added to 0.08 mL of pure water for dissolution, followed by the addition of 1.0 mL of acetonitrile, followed by continued stirring for 30 min, and then placed in a 5°C low temperature tank for stirring and crystallization, filtered, and dried in a 40°C blast drying oven for 24 h to obtain the crystal form II of the compound of formula 1, with a purity of 99.41% and 0.009% residual acetonitrile. The obtained sample was subjected to X-ray powder determination using Cu-ka rays, and its X-ray powder diffraction pattern was substantially consistent with that of Example 3.

[0100] Example 7: Preparation of Form III of the Compound of Formula 1

[0101] At 25°C, 20 mg of the compound of formula 1 was added to 0.12 mL of dimethyl sulfoxide solvent to obtain a clear solution, 0.5 mL of N, N-dimethylacetamide was added, stirred and crystallized, filtered, and dried in a vacuum drying oven at 60°C for 6 hours to obtain the crystal form III of the compound of formula 1. The obtained sample was subjected to X-ray powder determination using Cu-ka rays, and its spectrum had the diffraction angle, crystal plane spacing and relative intensity shown in Table 3, and its X-ray powder diffraction spectrum was basically as shown in Table 3. Figure 3 shown.

[0102] Table 3 Diffraction angle, interplanar spacing and relative intensity of the crystalline form III of the compound of formula 1

[0103]

[0104]

[0105] Example 8: Preparation of Form III of the Compound of Formula 1

[0106] At 25°C, 20 mg of the compound of formula 1 was added to 0.12 mL of dimethyl sulfoxide solvent to obtain a clear solution, 1.2 mL of N, N-dimethylacetamide was added, stirred and crystallized, filtered, and dried in a vacuum drying oven at 30°C for 24 hours to obtain Form III of the compound of formula 1. The obtained sample was subjected to X-ray powder determination using Cu-ka rays, and its X-ray powder diffraction pattern was basically consistent with that of Example 7.

[0107] Example 9: Preparation of Form IV of the Compound of Formula 1

[0108] At 60°C, 20 mg of the compound of formula 1 was added to 2 mL of tetrahydrofuran, suspended for 24 hours, filtered, and dried in a vacuum drying oven at 60°C for 6 hours to obtain the crystalline form IV of the compound of formula 1. The obtained sample was subjected to X-ray powder determination using Cu-ka rays, and its spectrum had the diffraction angle, crystal plane spacing and relative intensity shown in Table 4, and its X-ray powder diffraction spectrum was basically as shown in Table 4. Figure 4 shown.

[0109] Table 4 Diffraction angle, interplanar spacing and relative intensity of the crystal form IV of the compound of formula 1

[0110]

[0111]

[0112] Example 10: Preparation of Form IV of the Compound of Formula 1

[0113] At 50°C, 20 mg of the compound of formula 1 was added to 2 mL of 2-methyltetrahydrofuran, suspended for 12 hours, filtered, and dried in a vacuum drying oven at 30°C for 24 hours to obtain the crystalline form IV of the compound of formula 1. The obtained sample was subjected to X-ray powder determination using Cu-ka rays, and its X-ray powder diffraction pattern was basically consistent with that of Example 9.

[0114] Example 11: Preparation of Form V of the Compound of Formula 1

[0115] At 50°C, 20 mg of the compound of formula 1 was added to 2 mL of hexafluoroisopropanol, suspended for 24 hours, filtered, and dried in a vacuum drying oven at 60°C for 6 hours to obtain the crystalline form V of the compound of formula 1. The obtained sample was subjected to X-ray powder determination using Cu-ka rays, and its spectrum had the diffraction angle, interplanar spacing and relative intensity shown in Table 5, and its X-ray powder diffraction spectrum was basically as shown in Table 5. Figure 5 shown.

[0116] Table 5 Diffraction angle, interplanar spacing and relative intensity of the crystal form V of the compound of formula 1

[0117]

[0118]

[0119] Example 12: Preparation of Form V of the Compound of Formula 1

[0120] At 60° C., 20 mg of the compound of formula 1 was added to 2 mL of hexafluoroisopropanol, suspended for 12 h, filtered, and dried in a vacuum drying oven at 30° C. for 24 h to obtain the crystalline form V of the compound of formula 1. The obtained sample was subjected to X-ray powder determination using Cu-ka rays, and its X-ray powder diffraction pattern was basically consistent with that of Example 11.

[0121] Example 13: Preparation of Crystalline Form VI of the Compound of Formula 1

[0122] At 25°C, 20 mg of the compound of formula 1 was added to a mixed solvent of 1 mL of trifluoroethanol and 0.1 mL of water to obtain a clear solution, which was slowly evaporated at 5°C for 72 hours to obtain the crystalline form VI of the compound of formula 1. The obtained sample was subjected to X-ray powder determination using Cu-ka rays, and its spectrum had the diffraction angle, interplanar spacing and relative intensity shown in Table 6. Its X-ray powder diffraction spectrum was substantially as shown in Table 6. Figure 6 shown.

[0123] Table 6 Diffraction angle, interplanar spacing and relative intensity of the crystal form VI of the compound of formula 1

[0124]

[0125] Example 14: Preparation of Crystalline Form VI of the Compound of Formula 1

[0126] At 25°C, 20 mg of the compound of formula 1 was added to a mixed solvent of 1 mL of trifluoroethanol and 0.1 mL of water to obtain a clear solution, which was slowly evaporated at 35°C for 48 hours to obtain the crystalline form VI of the compound of formula 1. The obtained sample was subjected to X-ray powder determination using Cu-ka rays, and its X-ray powder diffraction pattern was basically consistent with that of Example 13.

[0127] Example 15: Preparation of Form VII of the Compound of Formula 1

[0128] The crystal form I of the compound of formula 1 was placed in a vacuum oven at 40°C and dried for 48 hours to obtain the crystal form VII of the compound of formula 1. The obtained sample was subjected to X-ray powder determination using Cu-ka rays, and its spectrum had the diffraction angle, interplanar spacing and relative intensity shown in Table 7. Its X-ray powder diffraction spectrum was basically as shown in Table 7. Figure 7 shown.

[0129] Table 7 Diffraction angle, interplanar spacing and relative intensity of the crystalline form VII of the compound of formula 1

[0130]

[0131] Example 16: Preparation of Form VII of the Compound of Formula 1

[0132] The crystal form I of the compound of formula 1 was placed in a vacuum oven at 60° C. and dried for 6 h to obtain the crystal form VII of the compound of formula 1. The obtained sample was subjected to X-ray powder determination using Cu-ka rays, and its X-ray powder diffraction pattern was basically consistent with that of Example 15.

[0133] Comparative Example 1: Preparation of Form A of the Compound of Formula 1

[0134] At room temperature, 20 mg of the compound of formula 1 was added to 2 mL of ethyl acetate, suspended at 25° C. for 24 h, filtered, and dried to obtain the crystalline form A of the compound of formula 1. The obtained sample was subjected to X-ray powder determination using Cu-ka rays, and its powder diffraction pattern was as follows: Figure 8 shown.

[0135] Comparative Example 2: Preparation of Form C of the Compound of Formula 1

[0136] At room temperature, 20 mg of the amorphous compound of Formula 1 was added to 2 mL of 1,4-dioxane, suspended at 25°C for 24 hours, filtered, and dried to obtain the crystalline form C of the compound of Formula 1. The obtained sample was subjected to X-ray powder determination using Cu-ka rays, and its powder diffraction pattern was as follows: Fig. 9 shown.

[0137] Test Example 1: Investigation of Stability of Influencing Factors

[0138] In order to investigate the stability of the new crystal form of the compound of formula 1 prepared in the present application, the crystal form II prepared in Example 3, the crystal form A prepared in Comparative Example 1, and the crystal form C prepared in Comparative Example 2 were placed under high temperature (60°C), high humidity (92.5% RH), and strong light irradiation (4500lx±500lx) for 30 days, respectively, and samples were taken for XRD and HPLC testing, and compared with the results of 0 day. The specific data are shown in Tables 8-10 and Figure 10-12 As shown:

[0139] Table 8 Stability of factors affecting the crystal form A of the compound of formula 1 of the present invention

[0140]

[0141]

[0142] Table 9 Stability of factors affecting the crystal form C of the compound of formula 1 of the present invention

[0143]

[0144] Table 10 Stability of factors affecting the crystal form II of the compound of formula 1 of the present invention

[0145]

[0146] From Table 8-10 and Figure 10-12 It can be seen that after being placed under the influencing factors for 30 days, the crystal form II did not undergo crystal transformation, and the purity did not decrease under high temperature and high humidity conditions, and the purity decreased slightly after being placed under light conditions for 30 days. Crystal forms A and C not only undergo crystal transformation under high humidity, but also have a higher decrease in purity than crystal form II under high temperature and light conditions. In summary, the crystal form II of the compound of formula 1 prepared in the present application has better crystal stability and chemical stability under the influencing factors.

[0147] Test Example 2: Accelerated and long-term stability studies

[0148] In order to investigate the stability of the new crystalline form of the compound of formula 1 prepared in the present application, the crystalline form II prepared in Example 3 and the crystalline form A prepared in Comparative Example 1 were placed under accelerated (25° C., 60% RH) and long-term (40° C., 75% RH) conditions for 1, 2, 3, and 6 months, respectively, and samples were taken for XRD and HPLC testing, and compared with the results of 0 day. The specific data are shown in Table 11 below:

[0149] Table 11 Comparison of long-term / accelerated stability of the compound of formula 1 in the present invention, Form A and Form II

[0150]

[0151] As can be seen from Table 11, Form II and Form A did not undergo crystal transformation after being placed under both accelerated and long-term conditions for 6 months, but Form A showed a significant decrease in purity after being placed under accelerated and long-term conditions for 6 months. In summary, Form II of the compound of Formula 1 prepared in the present application has excellent crystal stability and chemical stability under accelerated and long-term conditions.

[0152] Test Example 3: Solubility Investigation

[0153] In order to investigate the solubility of the crystalline form II, crystalline form A and crystalline form C of the compound of formula 1, the crystalline form II of the compound of formula 1 prepared in Example 3, the crystalline form A prepared in Comparative Example 1, and the crystalline form C prepared in Comparative Example 2 were placed in pure water to test their solubility at room temperature. The results are shown in Table 12:

[0154] Table 12 Solubility of Form II, Form A and Form C of Formula 1 in pure water

[0155] Sample Type Crystalline Form II Crystalline Form A Form C Solubility >200mg / mL >200mg / mL >200mg / mL

[0156] It can be seen from Table 12 that the solubility of Form II of the compound of Formula 1 in pure water is greater than 200 mg / mL.

[0157] Test Example 4: Hygroscopicity test

[0158] In order to investigate the hygroscopicity of the crystal form II of the compound of formula 1 prepared in the present application, the crystal form II of the compound of formula 1 prepared in Example 3, the crystal form A prepared in Comparative Example 1, and the crystal form C prepared in Comparative Example 2 were placed in a dynamic moisture adsorption instrument to investigate the weight change of the samples within the range of 0-98%-0 humidity. The hygroscopicity results of the crystal form II, crystal form A, and crystal form C of the compound of formula 1 are shown in Tables 13 and Figure 13-15 As shown:

[0159] Table 13 Hygroscopicity of Form II, Form A and Form C of Formula 1 at 80% RH to 98% RH

[0160]

[0161] From Table 13 and Figure 13-15 It can be seen that the crystalline form II of the compound of formula 1 has lower hygroscopicity than the crystalline form A and the crystalline form C, and has better quality controllability during the storage of the raw materials and preparations. Combining the results of test examples 1 and 4, it can be seen that the crystalline form II of the compound of formula 1 has lower hygroscopicity while maintaining high solubility, overcoming the defect of the existing crystalline form that it is easy to transform into a crystal due to high hygroscopicity.

[0162] Experimental Example 5: Pharmacokinetic Study in Beagle Dogs

[0163] (1) Purpose of the test

[0164] The concentration level of the raw material drug in plasma and its pharmacokinetic characteristics were investigated after a single oral administration of Form II and Form A samples of the compound of Formula 1 to beagle dogs at the same dosage.

[0165] (2) Materials and methods

[0166] ①Test drug

[0167] Crystalline Form II of the compound of Formula 1 prepared in Example 3;

[0168] The crystalline form A of the compound of formula 1 prepared in comparative example 1;

[0169] ② Experimental animals

[0170] There were 12 beagles, 6 females and 6 males.

[0171] ③Test methods

[0172] Different crystalline samples of the compound of formula 1 were orally administered to beagle dogs, and 0.2 mL of blood was collected from the jugular vein before administration and 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, and 72 h after administration, placed in an EDTA-K2 anticoagulant tube, centrifuged at 4500 r / min for 10 min, and 50 ul of the supernatant was separated and placed in a centrifuge tube, and stored in a -80°C refrigerator.

[0173] ④LC / MS / MS biological sample analysis:

[0174] Take 50 μL of plasma and mix it with 5 mL of working solution or blank dilution, add 150 μL of acetonitrile precipitant containing internal standard, vortex for 2 min, centrifuge at 12000 r / min for 10 min, take 20 μL of supernatant and mix it with 200 μL of acetonitrile aqueous solution (acetonitrile: water = 1:1), and inject 5 μL for analysis.

[0175] ⑤Test results:

[0176] The main pharmacokinetic parameters in plasma of beagle dogs after a single oral administration of different crystalline samples are shown in Table 14:

[0177] Table 14 Main pharmacokinetic parameters in plasma of beagle dogs after single oral administration of different crystalline samples

[0178]

[0179] It can be seen from Table 14 that the maximum blood drug concentration of the self-developed crystal form II in female / male beagle dogs is significantly higher than that of the original crystal form A; the crystal form II of the formula 1 compound has good bioavailability in beagle dogs.

[0180] In summary, the crystal form II of the compound of formula 1 prepared in the present application has improved crystal stability, chemical stability and bioavailability. The improvement of the photostability of the compound of formula 1 is not only conducive to reducing the content of photochemical degradation products produced during the storage of the raw material and the preparation, but also conducive to reducing the possibility of the compound causing photosensitivity reactions due to exposure to sunlight in patients receiving the corresponding drugs. In addition, the crystal form II has lower hygroscopicity while maintaining a high solubility, overcoming the defect of the existing crystal form that it is easy to transform into a crystal due to high hygroscopicity.

[0181] At the same time, the preparation conditions of the crystal form II of the present application are mild, the operation is simple, and the process reproducibility is good, so that the industrial production conditions can be controlled, which is conducive to large-scale industrialization. It is worth noting that although the second-class solvent acetonitrile is used in the preparation process of the crystal form II of the present application, the acetonitrile residue in the obtained crystal form II sample is extremely low, ensuring the controllable quality of the raw material drug.

[0182] It is obvious to those skilled in the art that various modifications and changes may be made to the compounds of the present application and their preparation methods without departing from the spirit or scope of the present application. Therefore, the scope of protection of the present application covers various modifications and changes made to the present application, as long as the modifications or changes are within the scope covered by the claims and their equivalent embodiments.

Claims

1. A crystalline form II of a compound of formula 1, characterized in that: The X-ray powder diffraction pattern of the crystalline form II has characteristic peaks at 2θ angles of 8.6±0.2°, 10.1±0.2°, 14.5±0.2°, 17.3±0.2°, 18.0±0.2°, 22.5±0.2°, 25.9±0.2° and 28.4±0.2°.

2. The crystal form II according to claim 1, characterized in that The X-ray powder diffraction pattern of the crystalline form II has characteristic peaks at 2θ angles of 8.6±0.2°, 10.1±0.2°, 14.5±0.2°, 17.3±0.2°, 18.0±0.2°, 22.2±0.2°, 22.5±0.2°, 22.7±0.2°, 25.9±0.2°, 27.8±0.2° and 28.4±0.2°.

3. The crystal form II according to claim 2, characterized in that The X-ray powder diffraction pattern of the crystalline form II has characteristic peaks at 2θ angles of 8.6±0.2°, 10.1±0.2°, 13.7±0.2°, 14.5±0.2°, 15.3±0.2°, 15.7±0.2°, 17.3±0.2°, 18.0±0.2°, 22.2±0.2°, 22.5±0.2°, 22.7±0.2°, 25.9±0.2°, 27.8±0.2° and 28.4±0.2°.

4. The crystal form II according to claim 3, characterized in that The X-ray powder diffraction pattern of the crystalline form II is substantially as shown in FIG2 .

5. A method for preparing the crystal form II according to any one of claims 1 to 4, characterized in that: The preparation method comprises the following steps: adding the compound of formula 1 into pure water to dissolve it, then adding acetonitrile to stir and crystallize it, filtering it, and drying it to obtain the crystal form II.

6. The method for preparing Form II according to claim 5, characterized in that: The volume ratio of the pure water to acetonitrile is 1:10 to 1:

60.

7. The method for preparing Form II according to claim 5, characterized in that: The crystallization temperature is 0-40°C.

8. The method for preparing Form II according to claim 5, characterized in that: The drying method is air drying or vacuum drying.

9. The method for preparing Form II according to claim 5, characterized in that: The drying temperature is 30-60°C.

Citation Information

Patent Citations

  • Crystals of quinoline derivative and preparation methods thereof

    CN102344438A

  • Application of anlotinib and pharmaceutically acceptable salts thereof in preparation of medicines for treating multiple myeloma

    CN113262223A

  • Combined pharmaceutical composition for treating proliferative diseases

    CN114984015A

  • Crystal habit of quinoline derivative and preparation method for crystalline powder thereof

    WO2020001406A1

  • Drug combination of quinoline derivative and Anti-CD47 antibody

    WO2023051669A1